Scientific Publications

Browse our collection of scientific publications on Immunotherapy to learn more about the latest research and developments in the field.

Scientific Publications Headers 9

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dimopoulos, MA., Moreau, P., Terpos, E., et al. Ann Oncol. 2021;32:309-322.

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Allen, PB., Savas, H., Evens, AM., et al. Blood. 2021;137:1318-1326.

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Kadauke, S., Myers, RM., Li, Y., et al. J Clin Oncol. 2021;39:920-930.

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

DiLillo, DJ., Olson, K., Mohrs, K., et al. Blood Adv. 2021;5:1291-1304.

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Nooka, AK., Weisel, K., van de Donk, NW., et al. Future Oncol. 2021 Mar 8. Epub ahead of print.

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Balzarotti, M., Magagnoli, M., Canales, MÁ., et al. Invest New Drugs. 2021 Feb 1. Epub ahead of print.

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

Danilov, AV., Spurgeon, SE., Siddiqi, T., et al. Invest New Drugs. 2021 Mar 8. Epub ahead of print.

Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL

Zheng, W., Wei, J., Zebley, C., et al. Blood. 2021 Mar 10. Epub ahead of print.

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells

Leivas, A., Risueño, RM., Guzmán, A., et al. Cancer Immunol Immunother. 2021 Mar 10. Epub ahead of print.

PD-1 blockade for untreated Hodgkin lymphoma

Moskowitz, AJ. PD-1 blockade for untreated Hodgkin lymphoma. Blood. 2021;137:1271-1272.

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Shoumariyeh, K., Jung, J., Rassner, M., et al. Ann Hematol. 2021 Mar 13. Epub ahead of print.

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Kuruvilla, J., Ramchandren, R., Santoro, A., et al. Lancet Oncol. 2021 Mar 12. Epub ahead of print.

Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma

Fernández, KS., Mavers, M., Marks, LJ., Agarwal, R. J Pediatr Hematol Oncol. 2021;43:e191-e194.

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

Armand, P., Lesokhin, A., Borrello, I., et al. Leukemia. 2021;35:777-786.

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos, M., Bringhen, S., Anttila, P., et al. Blood. 2021;137:1154-1165.

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Couturier, MA., Thomas, X., Raffoux, E., et al. Leuk Lymphoma. 2021;62:620-629.

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

Chari, A., Rodriguez-Otero, P., McCarthy, H., et al. Br J Haematol. 2021;192:869-878.

Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges

Bernhardt, MB., Militano, O., Honeyford, L., Zupanec, S. J Oncol Pharm Pract. 2021;27:376-388.

Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis

Chong, LL., Soon, YY., Soekojo, CY., et al. Crit Rev Oncol Hematol. 2021;159:103211.

Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis

Wang, N., Meng, Y., Wu, Y., et al. Immunotherapy. 2021;13:345-357.

Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Li, X., Zhou, M., Qi, J., et al. Clin Lymphoma Myeloma Leuk. 2021;21:e227-e247.

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

Fedorova, LV., Lepik, KV., Mikhailova, NB., et al. Ann Hematol. 2021;100:691-698.

Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study

Martinelli, G., Boissel, N., Chevallier, P., et al. Eur J Cancer. 2021;146:107-114.

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

Brown, PA., Ji, L., Xu, X., et al. JAMA. 2021;325:833-842.

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

Locatelli, F., Zugmaier, G., Rizzari, C., et al. JAMA. 2021;325:843-854.

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Martínez-López, J., Mustjoki, S., Porkka, K., et al. Leuk Lymphoma. 2021 Mar 2. Epub ahead of print.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau, P., Kumar, SK., San Miguel, J., et al. Lancet Oncol. 2021;22:e105-e118.

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

Jeryczynski, G., Antlanger, M., Duca, F., et al. ESMO Open. 2021 Mar 2. Epub ahead of print.

Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy

Wang, C., Liu, Y., Dong, L., et al. Clin Cancer Res. 2021 Mar 5. Epub ahead of print.

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Willier, S., Rothämel, P., Hastreiter, M., et al. Blood. 2021;137:1037-1049.

Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains

Choi, S., Pegues, MA., Lam, N., et al. Hum Gene Ther. 2021 Feb 22. Epub ahead of print.

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Voorhees, PM., Rodriguez, C., Reeves, B., et al. Blood Adv. 2021;5:1092-1096.

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Mohyuddin, GR., Rooney, A., Balmaceda, N., et al. Blood Adv. 2021;5:1097-1101.

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Daver, N., Salhotra, A., Brandwein, JM., et al. Am J Hematol. 2021 Feb 22. Epub ahead of print.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Da Vià, MC., Dietrich, O., Truger, M., et al. Nat Med. 2021 Feb 22. Epub ahead of print.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Munshi, NC., Anderson, LD Jr., Shah, N., et al. N Engl J Med. 2021;384:705-716.

CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia

Hu, Y., Zhou, Y., Zhang, M., et al. Clin Cancer Res. 2021 Feb 24. Epub ahead of print.

Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies

Al-Juhaishi, T., Ahmed, S. Curr Hematol Malig Rep. 2021 Feb 25. Epub ahead of print.

An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia

Venugopal, S., Daver, N., Ravandi, F. Curr Hematol Malig Rep. 2021 Feb 25. Epub ahead of print.

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia

Cook, G., Corso, A., Streetly, M., et al. Oncol Ther. 2021 Feb 25. Epub ahead of print.

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Sharman, JP., Brander, DM., Mato, AR., et al. Lancet Haematol. 2021 Feb 22. Epub ahead of print.

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

Ying, Z., He, T., Wang, X., et al. BMC Cancer. 2021;21:198.

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Gouill, S., Morschhauser, F., Chiron, D., et al. Blood. 2021;137: 877–887.

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Topp, MS., Gökbuget, N., Zugmaier, G., et al. Cancer. 2021;127:554-559.

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Salles, G., Długosz-Danecka, M., Ghesquières, H., Jurczak, W. Expert Opin Biol Ther. 2021 Feb 15. Epub ahead of print.

Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis

Hu, L., Charwudzi, A., Li, Q., et al. Ann Hematol. 2021 Feb 15. Epub ahead of print.

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Huang, H., Zhu, J., Yao, M., et al. J Hematol Oncol. 2021;14:25.

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

Awwad, MHS., Mahmoud, A., Bruns, H., et al. Leukemia. 2021 Feb 17. Epub ahead of print.

Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations

Shah, N., Sussman, M., Crivera, C., et al. Clin Drug Investig. 2021 Feb 18. Epub ahead of print.

Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond

Desai, S., Ansell, SM. Leuk Lymphoma. 2021 Feb 18. Epub ahead of print.

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22

Kantarjian, HM., Stock, W., Cassaday, RD., et al. Clin Cancer Res. 2021 Feb 18. Epub ahead of print.

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Stilgenbauer, S., Bosch, F., Ilhan, O., et al. Br J Haematol. 2021 Feb 19. Epub ahead of print.

CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial

Shao, M., Yu, Q., Teng, X., et al. Bone Marrow Transplant. 2021 Feb 19. Epub ahead of print.

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

Ragoonanan, D., Khazal, SJ., Abdel-Azim, H., et al. Nat Rev Clin Oncol. 2021 Feb 19. Epub ahead of print.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Uy, GL., Aldoss, I., Foster, MC., et al. Blood. 2021;137:751-762.

Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy

Khaldoyanidi, S., Nagorsen, D., Stein, A., et al. J Clin Oncol. 2021;39:419-432.

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies

Lussana, F., Gritti, G., Rambaldi, A. J Clin Oncol. 2021;39:444-455.

Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma

Komanduri, KV. J Clin Oncol. 2021;39:476-486.

Immunotherapy for Hematologic Malignancies

Craddock, C., Friedberg, JW. Journal of Clinical Oncology. 2021;39:343-345.

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

Kazandjian, D., Dew, A., Hill, E., et al. Oncologist. 2021 Feb 8. Epub ahead of print.

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Salles, G., Długosz-Danecka, M., Ghesquières, H., Jurczak, W. Expert Opin Biol Ther. 2021 Feb 15. Epub ahead of print.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Samur, MK., Fulciniti, M., Aktas Samur, A., et al. Nat Commun. 2021;12:868.

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study

Terpos, E., Raje, N., Croucher, P., et al. Blood Adv. 2021;5:725-736.

Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells

Wittmann Dayagi, T., Sherman, G., Bielorai, B., et al. Leuk Lymphoma. 2021 Feb 10. Epub ahead of print.

Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study

Gordan, L., Chang, M., Lafeuille, MH., et al. Drugs Real World Outcomes. 2021 Feb 9. Epub ahead of print.

Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia

Harvanová, Ľ., Štulajterová, V., Guman, T., et al. Neoplasma. 2021 Feb 11. Epub ahead of print.

Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia

Saleh, K., Chahine, C., Khalife, N. Future Oncol. 2021 Feb 12. Epub ahead of print.

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Danhof, S., Rasche, L., Mottok, A., et al. Ann Hematol. 2021 Feb 11. Epub ahead of print.

Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia

Wang, S., Wang, X., Ye, C., et al. Am J Hematol. 2021 Feb 13. Epub ahead of print.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Neelapu, S.S., Adkins, S., Ansell, S.M., et al. J Immunother Cancer. 2020;8;e001235

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Avet-Loiseau, H., San-Miguel, J., Casneuf, T., et al. J Clin Oncol. 2021 Jan 29. Epub ahead of print.

Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells

Shalabi, H., Gust, J., Taraseviciute, A., et al. Nat Rev Clin Oncol. 2021 Jan 25. Epub ahead of print.

CAR T cell therapies for patients with multiple myeloma

Mikkilineni, L., Kochenderfer, JN. Nat Rev Clin Oncol. 2021;18:71-84.

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Armand, P., Janssens, A., Gritti, G., et al. Blood. 2021;137:637–645.

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Daher, M., Basar, R., Gokdemir, E., et al. Blood. 2021;137:624–636.

An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models

Yu, SF., Lee, DW., Zheng, B., et al. Mol Cancer Ther. 2021;20:340-346.

Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T cells for the Treatment of Acute Myeloid Leukemia

Lichtman, EI., Du, H., Shou, P., et al. Clin Cancer Res. 2021 Feb 2. Epub ahead of print.

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Dimopoulos, MA., Leleu, X., Moreau, P., et al. Leukemia. 2021;35:562-572.

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Ortíz-Maldonado, V., Rives, S., Castellà, M., et al. Mol Ther. 2021;29:636-644.

Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review

Shragai, T., Gatt, M., Lavie, N., et al. Eur J Haematol. 2021;106:184-195.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

Moreau, P., Hebraud, B., Facon, T., et al. Immunotherapy. 2021;13:143-154.

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series

McMillan, A., O'Neill, AT., Townsend, W., et al. Br J Haematol. 2021;192:e84-e87.

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Balzarotti, M., Magagnoli, M., Canales, MÁ., et al. Invest New Drugs. 2021 Feb 1. Epub ahead of print.

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

Fedorova, LV., Lepik, KV., Mikhailova, NB., et al. Ann Hematol. 2021 Feb 2. Epub ahead of print.

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Vozella, F., Siniscalchi, A., Rizzo, M., et al. Ann Hematol. 2021 Feb 2. Epub ahead of print.

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Brivio, E., Chantrain, CF., Gruber, TA., et al. Br J Haematol. 2021 Feb 2. Epub ahead of print.

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

Wei, AH., Ribera, JM., Larson, RA., et al. Leukemia. 2021 Feb 4. Epub ahead of print.

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis

Luo, C., Wu, G., Huang, X., et al. Sci Rep. 2021;11:3255.

Emicizumab for the treatment of acquired hemophilia A

Knoebl, P., Thaler, J., Jilma, P., et al. Blood. 2021;137:410–419.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Gauthier, J., Bezerra, ED., Hirayama, AV., et al. Blood. 2021;137:323–335.

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Zhao, Y., Aldoss, I., Qu, C., et al. Blood. 2021;137:471–484.

Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Song, Q., Wang, X., Wu, X., et al. Blood. 2021 Jan 27. Epub ahead of print.

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects

Vasileiou, S., Lulla, PD., Tzannou, I., et al. J Clin Oncol. 2021 Jan 28. Epub ahead of print.

Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia

Lin, G., Zhang, Y., Yu, L., Wu D. Mol Med Rep. 2021;23:208.

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Wu, Y., Chen, D., Lu, Y., et al. Cancer Gene Ther. 2021 Jan 29. Epub ahead of print.

A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients

Chen, S., Kiguchi, T., Nagata, Y., et al. Int J Hematol. 2021 Jan 28. Epub ahead of print.

Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity

Schmidts, A., Wehrli, M., Maus, MV. Annu Rev Med. 2021;72:365-382.

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma

Fang, Y., Hou, J. Mil Med Res. 2021;8:9.

Multiple myeloma

van de Donk, NWCJ., Pawlyn, C., Yong, KL. Lancet. 2021;397:410-427.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Usmani, SZ., Hoering, A., Ailawadhi, S., et al. Lancet Haematol. 2021;8:e45-e54.

Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology

Schmidt, P., Raftery, MJ., Pecher, G. Front Immunol. 2021;11:611163.

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy

Brechbühl, S., Bacher, U., Jeker, B., Pabst, T. Mediterr J Hematol Infect Dis. 2021;13:e2021012.

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

Buechner, J., Grupp, SA., Hiramatsu, H., et al. Blood Adv. 2021;5:593-601.

TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther

Zeidan, AM., Komrokji, RS., Brunner, AM. Expert Rev Anticancer Ther. 2021 Jan 19. Epub ahead of print.

Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Aging Cell

Hamilton, JAG., Lee, MY., Hunter, R., et al. Aging Cell. 2021 Jan 22. Epub ahead of print.

CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma

Zhou, X., Ge, T., Li, T., et al. Cancer Immunol Immunother. 2021 Jan 18. Epub ahead of print.

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Roselli, E., Faramand, R., Davila, ML. J Clin Invest. 2021;131:e142030.

Elotuzumab in the treatment of relapsed and refractory multiple myeloma

Grosicki, S., Bednarczyk, M., Barchnicka, A., Grosicka, O. Future Oncol. 2021 Jan 22. Epub ahead of print.

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy

Alhallak, K., Sun, J., Wasden, K., et al. Leukemia. 2021 Jan 21. Epub ahead of print. 

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

Lassiter, G., Bergeron, C., Guedry, R., et al. Curr Oncol. 2021;28:640-660. 

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells

Russkamp, NF., Myburgh, R., Kiefer, JD., et al. Exp Hematol. 2021 Jan 20. Epub ahead of print.

Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients

Fan, F., Yoo, HJ., Stock, S., et al. Int J Cancer. 2021 Jan 15. Epub 2020 Jul 28.

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Gudiol, C., Lewis, RE., Strati, P., Kontoyiannis, DP. Lancet Haematol. 2021 Jan 15. Epub ahead of print.

A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions

Halford, Z., Coalter, C., Gresham, V., Brown, T. Ann Pharmacother. 2021 Jan 13. Epub ahead of print.

CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells

Bunse, M., Pfeilschifter, J., Bluhm, J., et al. Nat Commun. 2021;12:240.

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies

Lussana, F., Gritti, G., Rambaldi, A. J Clin Oncol. 2021 Jan 12. Epub ahead of print.

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Shi, Y., Wu, J., Wang, Z., et al. J Hematol Oncol. 2021;14:12.

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas

Reagan, PM., Friedberg, JW. Future Oncol. 2021 Jan 15. Epub ahead of print.

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Ansell, SM., Maris, M., Lesokhin, AM., et al. Clin Cancer Res. 2021 Jan 15. Epub ahead of print.

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Martino, M., Paviglianiti, A. Expert Opin Biol Ther. 2021 Jan 13. Epub ahead of print.

Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma

Al-Hadidi, SA., Lee, HJ. JCO Oncol Pract. 2021 Jan 12. Epub ahead of print.

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies

Schmid, C., Kuball, J., Bug, G. J Clin Oncol. 2021 Jan 12. Epub ahead of print.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

Kapp-Schwoerer, S., Weber, D., Corbacioglu, A., et al. Blood. 2020;136:3041-3050.

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Kadauke, S., Myers, RM., Li, Y., et al. J Clin Oncol. 2021 Jan 8. Epub ahead of print.

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Benjamin, R., Graham, C., Yallop, D., et al. Lancet. 2020;396:1885-1894.

Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma

Al-Hadidi, SA., Lee, HJ. JCO Oncol Pract. 2021 Jan 12. Epub ahead of print.

Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL

Tan, Y., Pan, J., Deng, B., et al. Cancer Immunol Immunother. 2021 Jan 8. Epub ahead of print.

Next-generation cell therapies: the emerging role of CAR-NK cells

Basar, R., Daher, M., Rezvani, K. Blood Adv. 2020;4:5868-5876.

Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis

Wang, N., Meng, Y., Wu, Y., et al. Immunotherapy. 2021 Jan 7. Epub ahead of print.

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Othman, T., Herrera, A., Mei, M. Curr Hematol Malig Rep. 2021 Jan 6. Epub ahead of print.

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

Feng, J., Xu, H., Cinquina, A., et al. Stem Cell Rev Rep. 2021 Jan 6. Epub ahead of print.

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Martino, M., Paviglianiti, A. Expert Opin Biol Ther. 2021 Jan 13. Epub ahead of print.

Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments

Geis, M., Nowotny, B., Bohn, MD., et al. Commun Biol. 2021;4:44.

Preclinical development of CD126 CAR-T cells with broad antitumor activity

Mishra, AK., Kemler, I., Dingli, D. Blood Cancer J. 2021;11:3.

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression

Costa, F., Marchica, V., Storti, P., et al. Cancers (Basel). 2021;13:E164.

Preclinical and Clinical Chimeric Antigen Receptor Therapy for Hematological Malignancies

Guo, Z., Tu, S., Yu, S., et al. Cancer Sci. 2021 Jan 8. Epub ahead of print.

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy

Park, SS., Min Byun, J., Yoon, SS., et al. Br J Haematol. 2020 Dec 27.Epub ahead of print.

Leukemic Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia

Cox, MJ., Lucien, F., Sakemura, R., et al. Mol Ther. 2020 Dec 31. Epub ahead of print.

Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis

Mian, A., Wei, W., Winter, AM., et al. Leuk Lymphoma. 2020 Dec 29. Epub ahead of print.

Monoclonal antibodies in frontline acute lymphoblastic leukemia

Chew, S., Jammal, N., Kantarjian, H., et al. Best Pract Res Clin Haematol. 2020;33:101226

Antibody based therapy in relapsed acute lymphoblastic leukemia

Jammal, N., Chew, S., Jabbour, E., Kantarjian, H. Best Pract Res Clin Haematol. 2020;33:101225.

How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?

Zhang, M., Huang, H. Front Immunol. 2020;11:611710.

A real-time quantitative PCR targeting the viral vector for the monitoring of patients treated with axicabtagene ciloleucel

Baras, A., Bocket, L., Beauvais, D., et al. J Mol Diagn. 2020 Dec 29. Epub ahead of print.

Cytokines in CAR T Cell-Associated Neurotoxicity

Gust, J., Ponce, R., Liles, WC., et al. Front Immunol. 2020;11:577027.

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Han, D., Xu, Z., Zhuang, Y., et al. J Cancer. 2021;12:326-334.

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis

Giri, S., Grimshaw, A., Bal, S., et al. JAMA Oncol. 2020 Sep 24. Epub ahead of print.

Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia

Contreras, CF., Higham, CS., Behnert, A., et al. Pediatr Blood Cancer. 2021;68:e28718.

Novel targeted therapies of T cell lymphomas

Iżykowska, K., Rassek, K., Korsak, D., Przybylski, GK. J Hematol Oncol. 2020;13:176.

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Bonello, F., Grasso, M., D'Agostino, M., et al. Pharmaceuticals (Basel). 2020;14:E20.

Anti-body building: The exercise of advancing immune based myeloma therapies

Richter, J., Thibaud, S. Blood Rev. 2020 Dec 28. Epub ahead of print.

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Los-Arcos, I., Iacoboni, G., Aguilar-Guisado, M., et al. Infection. 2020 Sep 26. Epub ahead of print.

CAR-T cell therapy and infection: a review

Bupha-Intr, O., Haeusler, G., Chee, L., et al. Expert Rev Anti Infect Ther. 2020 Dec 31. Epub ahead of print. 

Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia

Sharman, JP., Burke, JM., Yimer, HA., et al. Leuk Lymphoma. 2020 Nov 26. Epub ahead of print.

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Cortes, JE., de Lima, M., Dombret, H., et al. J Hematol Oncol. 2020;13:137.

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Dreger, P., Dietrich, S., Schubert, ML., Blood Adv. 2020;4:6157-6168.

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials

Xiang, X., He, Q., Ou, Y., et al. Front Pharmacol. 2020;11:544754

Investigational drugs for the treatment of diffuse large B-cell lymphoma

Patriarca, A., Gaidano, G., Expert Opin Investig Drugs, 2020 Dec 21. Epub Ahead of print.

New agents and regimens for diffuse large B cell lymphoma

Wang, L., Li, LR., Young, KH. J Hematol Oncol. 2020;13:175

Current Status on Therapeutic Molecules Targeting Siglec Receptors

Lenza, MP,, Atxabal, U., Oyenarte, I., Jiménez-Barbero, J. et al. Cells. 2020;9:2691

A critical role for fas-mediated off-target tumor killing in T cell immunotherapy

Upadhyay, R., Boiarsky, JA., Pantsulaia, G. et al. Cancer Discov. 2020 Dec 17. Epub ahead of print.

Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma

Touzeau, C., Antier, C., Moreau, P. Future Oncol. 2020 Dec 8. Epub ahead of print.

Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Queudeville, M., Schlegel, P., Heinz, AT., et al. Eur J Haematol. 2020 Dec 15. Epub ahead of print.

E3 Ubiquitin Ligase Cbl-b and its potential therapeutic implications for immunotherapy

Jafari, D., Mousavi, MJ., Keshavarz Shahbaz, S., et al. Clin Exp Immunol. 2020 Dec 11. Epub ahead of print.

Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy

Pan, J., Deng, B., Ling, Z., et al. J Cell Mol Med. 2020 Dec 12. Epub ahead of print.

Investigational drugs for the treatment of diffuse large B-cell lymphoma

Patriarca, A., Gaidano, G. Expert Opin Investig Drugs. 2020 Dec 9. Epub ahead of print.

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Laliberté, F., Raut, M., Yang, X., et al. Target Oncol. 2020 Dec 7. Epub ahead of print.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Roussel, M., Moreau, P., Hebraud, B., et al. Lancet Haematol. 2020;7:e874-e883.

Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Di Rocco, A., Cuneo, A., Di Rocco, A., et al. Leuk Lymphoma. 2020 Dec 4. Epub ahead of print.

Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

Badar, T., Szabo, A., Dinner, S., et al. Cancer. 2020 Dec 1. Epub ahead of print.

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Lim, JQ., Huang, D., Tang, T., et al. Leukemia. 2020 Dec;34:3413-3419.

Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis

Satake, A., Konishi, A., Azuma, Y., et al. Eur J Haematol. 2020;105:704-711.

Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma

Durie, BGM., Kumar, SK., Usmani, SZ., et al. Am J Hematol. 2020;95:1486-1494.

Outcome of COVID-19 in multiple myeloma patients in relation to treatment

Susek, KH., Gran, C., Ljunggren, HG., et al. Eur J Haematol. 2020;105:751-754.

Recent Advances in the Treatment of Patients with Multiple Myeloma

Legarda, MA., Cejalvo, MJ., de la Rubia, J. Cancers (Basel). 2020;12:E3576.

Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties

Haidar, G., Garner, W., Hill, JA. Curr Opin Infect Dis. 2020;33:449-457.

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Yilmaz, A., Cui, H., Caligiuri, MA., Yu, J. J Hematol Oncol. 2020;13:168.

Complement Activation in the Treatment of B-Cell Malignancies

Zent, CS., Pinney, JJ., Chu, CC., Elliott, MR. Antibodies (Basel). 2020;9:68.

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

Roex, G., Timmers, M., Wouters, K., et al. J Hematol Oncol. 2020;13:164.

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.

Daher, M., Rezvani, K. Cancer Discov. 2020 Dec 4. Epub ahead of print.

What is the future of immunotherapy in multiple myeloma?

Rasche, L., Hudecek, M., Einsele, H. Blood. 2020;136:2491-2497.

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

Stock, W., Martinelli, G., Stelljes, M., et al. Cancer. 2020 Nov 24. Epub ahead of print.

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis

Guha A, Addison D, Jain P, et al. Biol Blood Marrow Transplant. 2020;26:2211-2216.

Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties

Haidar, G., Garner, W., Hill, JA. Curr Opin Infect Dis. 2020;33:449-457.

Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis

Satake, A., Konishi, A., Azuma, Y., et al. Eur J Haematol. 2020;105:704-711.

Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Chen, YH., Zhang, X., Cheng, YF., et al. Cytotherapy. 2020;22:755-761.

Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells

Štach, M., Ptáčková, P., Mucha, M., et al. Cytotherapy. 2020 Dec;22:744-754.

Obinutuzumab-Related Adverse Events: A Systematic Review and Meta-Analysis

Amitai, I., Gafter-Gvili, A., Shargian-Alon, L., et al. Hematol Oncol. 2020 Nov 30. Epub ahead of print.

Fundamentals of immunology for understanding immunotherapy for lymphoma

Ansell, SM.. Blood Adv. 2020;4:5863-5867.

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Vercellino, L., Di, Blasi R., Kanoun, S., et al. Blood Adv. 2020;4:5607-5615.

A Primer on CAR-T Therapy: What Does It Mean for Pathologists?: A Summary Guidance From the College of American Pathologists CAR-T Workgroup

Cushman-Vokoun, AM., Voelkerding, KV., Fung, MK., et al. Arch Pathol Lab Med. 2020 Nov 25. Epub ahead of print.

The toxicity of cell therapy: Mechanism, manifestations, and challenges

Jin, Y., Dong, Y., Zhang, J., et al. J Appl Toxicol. 2020 Nov 25. Epub ahead of print.

Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy - what are we doing; where are we going?

Bechman, N., Maher, J. Expert Opin Biol Ther. 2020 Nov 26. Epub ahead of print.

CAR-T cell therapy and infection: a review

Bupha-Intr, O., Haeusler, G., Chee, L., et al. Expert Rev Anti Infect Ther. 2020 Nov 30. Epub ahead of print.

Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy

Cortés-Selva, D., Dasgupta, B., Singh, S., Grewal, IS. Trends Pharmacol Sci. 2020 Nov 26. Epub ahead of print.

Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management

Li, S., Wang, X., Yuan, Z., et al. Clin Cancer Res. 2020 Nov 24. Epub ahead of print

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hamadani, M., Radford, J., Carlo-Stella, C., et al. Blood. 2020;00:7512.

Combining T-cell–specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors

Frank, AM., Braun, AH., Scheib, L., et al. Blood Adv. 2020;4:5702–5715.

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia

An, F., Wang, H., Liu, Z., et al. Nat Commun. 2020;11:5928.

Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series

Luttwak, E., Hagin, D., Perry, C., et al. Bone Marrow Transplant. 2020 Nov 23. Epub ahead of print.

C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Jacobson, CA., Maus, MV. Blood Adv. 2020;4:5858-5862.

Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation

Hua, J., Zhang, J., Zhang, X., et al. Bone Marrow Transplant. 2020 Nov 24. Epub ahead of print.

Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL

Sheth, V., Gauthier, J. Bone Marrow Transplant. 2020 Nov 24. Epub ahead of print.

How to manage patients with corticosteroids in oncology in the era of immunotherapy?

Aldea, M., Orillard, E., Mansi, L., et al. Eur J Cancer. 2020 Nov 16. Epub ahead of print.

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors

Londoño, MC., Reig, M., On Behalf Of The Retoinmuno Multidisciplinary Group. Cancers (Basel). 2020;12:E3446.

Introduction to "Immunotherapies for Multiple Myeloma"

Offidani, M., Petrucci, MT. Pharmaceuticals. 2020;13:396.

Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma

Takheaw, N., Sittithumcharee, G., Kariya, R., et al. Cancer Immunol Immunother. 2020 Nov 19. Epub ahead of print.

Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020

Demel, I., Bago, JR., Hajek, R., Jelinek, T. Br J Haematol. 2020 Nov 20. Epub ahead of print.

Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics

Han, X., Li, H., Zhou, D., et al. Acc Chem Res. 2020;53:2521-2533.

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies

Lin, WY., Wang, HH., Chen, YW., et al. Int J Mol Sci. 2020;21:E8655.

Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells

Wang, C., Sun, C., Li, M., et al. J Cell Physiol. 2020 Nov 18. Epub ahead of print.

The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults

Ottaviano, G., Baird, S., Bonney, D., et al. Br J Haematol. 2020 Nov 20. Epub ahead of print.

Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9

Liu, L., Bi, E., Ma, X., et al. Nat Commun. 2020;11:5902.

Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity

Rafei, H., Daher, M., Rezvani, K. Br J Haematol. 2020 Nov 20. Epub ahead of print.

CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before

Ghilardi, G., Braendstrup, P., Chong, EA., et al. Br J Haematol. 2020 Nov 21. Epub ahead of print.

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Ljungman, P., Mikulska, M., de la Camara, R., et al. Bone Marrow Transplant. 2020;55:2071-2076. 

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Gotti, M., Defrancesco, I., D'Angelo, M., et al. Front Immunol. 2020;11:565236.

Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals

Ortiz de Landazuri, I., Egri, N., Muñoz-Sánchez, G., et al. Front Immunol. 2020;11:573179. 

Emerging agents and regimens for multiple myeloma

Yang, Y., Li, Y., Gu, H., et al. J Hematol Oncol. 2020;13:150.

The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

Tzogani, K., Penttilä, K., Lähteenvuo, J., et al. Oncologist. 2020 Nov 11. Epub ahead of print.

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Ogiya, D., Liu, J., Ohguchi, H., et al. Blood. 2020;136:2334-2345.

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Ghafouri, S., Timmerman, J., Larson, S., Mead, MD. Bone Marrow Transplant. 2020 Nov 10. Epub ahead of print.

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Klein, C., Jamois, C., Nielsen, T. Expert Opin Biol Ther. 2020 Nov 9. Epub ahead of print.

Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies

Li, L., Chai, Y., Wu, C., Zhao, L. Expert Rev Hematol. 2020 Nov 10. Epub ahead of print.

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Gang, M., Marin, ND., Wong, P., et al. Blood. 2020;136:2308-2318.

Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers

Saini, SK., Ørskov, AD., Bjerregaard, AM., et al. Nat Commun. 2020;11:5660.

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Gaudio, E., Tarantelli, C., Spriano, F., et al. Haematologica. 2020;105:2584-2591.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Pasquini, MC., Hu, ZH., Curran, K., et al. Blood Adv. 2020;4:5414–5424.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

Spiegel, JY., Dahiya, S., Jain, MD., et al. Blood. 2020 Nov 6. Epub ahead of print.

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy

Belin, C., Devic, P., Ayrignac, X., et al. Sci Rep. 2020;10:18997.

Bispecific antibodies in acute lymphoblastic leukemia therapy

Chitadze, G., Laqua, A., Lettau, M., et al. Expert Rev Hematol. 2020 Nov 4. Epub ahead of print.

Developing Cell Therapies as Drug Products

Ciccocioppo, R., Comoli, P., Astori, G., et al. Br J Pharmacol. 2020 Nov 3. Epub ahead of print.

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Topp, MS., Gökbuget, N., Zugmaier, G., et al. Cancer. 2020 Nov 3. Epub ahead of print.

Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies

El-Khazragy, N., Ghozy, S., Emad, P., et al. Immunotherapy. 2020 Nov 5. Epub ahead of print. 

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Couturier, MA., Thomas, X., Raffoux, E., et al. Leuk Lymphoma. 2020 Nov 6.  Epub ahead of print.

Systematic review and meta-analysis on CAR-T therapy in ALL patients

Anagnostou, T., Riaz, IB., Hashmi, SK., et al. Lancet Haematol. 2020;7:e816-e826.

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Foà, R., Bassan, R., Vitale, A., et al. N Engl J Med. 2020;383:1613-1623.

CAR-T cells: the Chinese experience

Wang, L., Tan Su Yin, E., Zhao, H., et al. Expert Opin Biol Ther. 2020;20:1293-1308. 

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz, H., Ozbalak, M., Karadurmus, N., et al. Ann Hematol. 2020;99:2565-2576.

Advances in chimeric antigen receptor T cells

Beyar-Katz, O., Gill, S., Curr Opin Hematol. 2020;27:368-377.

Pembrolizumab for the treatment of Hodgkin Lymphoma

Al Hadidi, SA., Lee HJ., Expert Opin Biol Ther. 2020;2:1275-1282. 

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Le Gouill, S., Beldi-Ferchiou, A., Alcantara, M., et al. Lancet Haematol. 2020;7:e798-e807. 

Brentuximab plus nivolumab for older patients with Hodgkin lymphoma

Cheson, BD., Bartlett, NL., LaPlant, B., et al. Lancet Haematol. 2020;7:e808-e815. 

The tumor microenvironment of lymphomas: insights into the potential role and modes of actions of checkpoint inhibitors

Menter, T., Tzankov, A., Dirnhofer, S., Hematol Oncol. 2020 Oct 26. Epub ahead of print.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

Shah, NN., Ahn, KW., Litovich, CA., et al. Blood. 2020 Oct 29. Epub ahead of print.

Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies

Leick, MB., Maus, MV., Frigault, MJ., Mol Ther. 2020 Oct 29. Epub ahead of print.

Natural Killer Cells in Immunotherapy: Are We Nearly There?

Bachiller, M., Battram, A.M., Perez-Amill, L., Martín-Antonio B., Cancers (Basel). 2020 Oct 27;12:E3139.

Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective

Córdova-Bahena, L., Velasco-Velázquez, M.A., Rev Invest Clin. 2020 Oct 20;73(5). Epub ahead of print.

IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives

Lapenta, C., Gabriele, L., Santini, SM., Vaccines (Basel). 2020 Oct 19;8(4):E617.

Cancer immunotherapy via targeted TGF-β signalling blockade in T H cells

Li, S., Liu, M., Do, MH., et al. Nature. 2020 Oct 21. Epub ahead of print.

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

de Jonge A.V., Mutis T., Roemer M.G.M., et al. Cancers (Basel). 2020 Oct 20;12(10):E3052.

The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma

Wang, X., Huynh, C., Urak, R., et al. Cancer Immunol Res. 2020 Oct 22. Epub ahead of print.

Human CXCR5 + PD-1 + CD8 T cells in healthy individuals and patients with hematologic malignancies

Hofland, T, Martens, AWJ., van Bruggen, JAC., et al. Eur J Immunol. 2020 Oct 24. Epub ahead of print.

Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia

Contreras, CF., Higham, CS., Behnert, A., et al. Pediatr Blood Cancer. 2020 Oct 24. Epub ahead of print.

Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology

DiNatale, RG., Hakimi, AA., Chan, TA., Hum Mol Genet. 2020 Oct 20;29:R214-R225.

Implications of metabolism-driven myeloid dysfunctions in cancer therapy

Strauss L., Guarneri V., Gennari A., Sica A., Cell Mol Immunol. 2020 Oct 19:1–13. Epub ahead of print.

Early 3+3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors

Rahma, OE., Reuss, JE., Giobbie-Hurder, A., et al. Clin Cancer Res. 2020 Oct 20. Epub ahead of print.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Shah, N., Aiello, J., Avigan, DE., et al. 2020;8:e000734.

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Deng, Q, Han, G., Puebla-Osorio, N., et al. Nat Med. 2020 Oct 5. Epub ahead of print.

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Cappell, KM., Sherry, RM., Yang, JC., et al. Journal of Clinical Oncology. 2020 Oct 6;33021872. Epub ahead of print

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome

Kittai, AS., Bond, DA., William, B, et al. Blood Adv. 2020;4: 4648–4652

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

Sermer, D, Batlevi, C., Palomba, ML., et al. Blood Adv. 2020;4: 4669–4678

Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy

Chow, VA., Gopal, AK., Gauthier, J., et al. Blood Adv. 2020;4: 4869–4872

How I treat relapsed acute lymphoblastic leukemia in the pediatric population

Hunger, SP., Raetz, EA., Blood. 2020;136:1803–1812

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia

Boroojerdi, MH., Rahbarizadeh, F, Kozani PS., et al. Med Oncol. 2020;37:100

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

Leong, S., Inglott, S., Papaleonidopoulou, F., et al. Blood Adv. 2020;4:4665-4668

Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities

Magnani, CF., Gaipa, G., Lussana, F., et al. J Clin Invest. 2020:138473. Epub ahead of print.

B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives

Sellner, L., Fan, F., Giesen, N., et al. Int J Cancer. 2020;147:2029-2041

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma

Tong C., Zhang, Y., Liu Y., et al. Blood. 2020;136:1632-1644

Bone morphogenetic protein 7 promotes resistance to immunotherapy

Cortez, MA., Masrorpour, F., Ivan, C., et al. Nat. Commun. 2020,11:4840

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Parker, KR., Migliorini, D., Perkey, E., et al. Cell. 2020;183:126-142.

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Pillarisetti, K., Powers, G., Luistro, L., et al. Blood Adv. 2020;4:4538–4549.

The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome

Foskolou, IP., Barbieri, L., Vernet, A., et al. Blood Adv. 2020;4:4483–4493.

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Kichenadasse, G., Miners, JO., Mangoni, AA., et al. J Natl Compr Canc Netw. 2020;18:11911199. 

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

Gao, Y., Nihira, NT., Bu, X., et al. Nat Cell Biol. 2020;22:1064-1075. 

Immuno-oncology drug development forges on despite COVID-19

Upadhaya, S., Hubbard-Lucey, VM., Yu, JX., Nat Rev Drug Discov. 2020 Sep 18.  Epub ahead of print. 

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Ramos, C.A., Grover NS., Beaven, AW., et al. J Clin Oncol. 2020 Jul 23:JCO2001342. Epub ahead of print. 

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

Fultang, L., Booth, S., Yogev, O., et al. Blood. 2020;136:1155–1160. 

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas

Neuwelt A., Al-Juhaishi T., Davila E., Haverkos B., Blood Adv. 2020;4:4256-4266. 

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

Hashmi, H., Mirza, AS., Darwin, A., et al. Blood Adv. 2020;4:4086-4090. 

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Stenger, D., Stief, T.A., Kaeuferle, T., et al. Blood. 2020;136:1407-1418. 

Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting

Ghesquieres, H., Salles, G., J Clin Oncol. 2020;38:3085-3087. 

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Abramson, JS., Palomba, ML., Gordon, LI., et al. Lancet. 2020;396:839-852. 

Exploring the NK cell platform for cancer immunotherapy

Myers, JA., Miller, JS., Nat Rev Clin Oncol. 2020 Sep 15. Epub ahead of print. 

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, H., Orhan, A., Christensen, JP., et al. Br J Cancer. 2020 Sep 15. Epub ahead of print. 

Human immunology and immunotherapy: main achievements and challenges

Varadé J., Magadán S., González-Fernández Á., Cell Mol Immunol. 2020 Sep 2:1–24. Epub ahead of print. 

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Wudhikarnl K., Palomba, ML., Pennisi, M., et al. Blood Cancer J. 2020;10:79. 

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Cader, FZ., Hu, X., Goh, WL., et al. Nat Med. 2020;26:1468-1479. 

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Biran, N., Ip, A., Ahn, J., et al. Lancet Rheumatol. 2020;2:e603-e612.

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies 

Einsele, H., Briones, J., Ciceri, F., et al. HemaSphere. 2020;4:e423.  
 

Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients 

Fan, F., Yoo, HJ., Stock, S., et al. Int J Cancer. 2020 Jul 19. Epub ahead of print. 

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma 

Shah N., Aiello J., Avigan, DE., et al. Journal for ImmunoTherapy of Cancer. 2020;8:e000734. 

The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 

Psaltopoulou, T., et al. HemaSphere. 2020;4(3):e409. 

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT.

Yakoub-Agha, I., Chabannon, C., Bader, P., et al. Haematologica. 2020;105:297-316.  

Meeting report of the 2nd European CAR T-Cell meeting in 2020

This report provides a summary of the meeting with links to recorded sessions.

  

Scientific Publications Headers 10

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy 

Lekakis, L.J., Moskowitz, C.H., HemaSphere. 2019;3:e295.  

Delivering on the Promise: Innovative Therapies and the Quest for (Real) Patient Benefit 

Doeswijk, R., Hemasphere. 2019;3:e298.  

Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL 

DiNofia, AM., Maude, SL., HemaSphere. 2019;3:e279.  

Meeting report of the 1st European CAR T-Cell meeting in 2019

This report provides a summary of the meeting with links to recorded sessions.

 

Last Updated on Tuesday 23 March 2021.